| # | Drug | Count |
|---|---|---|
| 0 | AMBRISENTAN | 403 |
| 1 | TREPROSTINIL | 334 |
| 2 | SILDENAFIL CITRATE | 304 |
| 3 | NATALIZUMAB | 241 |
| 4 | TADALAFIL | 238 |
| 5 | EPOPROSTENOL | 194 |
| 6 | MACITENTAN | 145 |
| 7 | SILDENAFIL | 142 |
| 8 | ECULIZUMAB | 133 |
| 9 | WARFARIN | 124 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | EPOPROSTENOL | 194 | 0.0148 |
| 1 | C1 ESTERASE INHIBITOR RECOMBINANT | 67 | 0.0104 |
| 2 | LARONIDASE | 38 | 0.0092 |
| 3 | ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN | 28 | 0.0074 |
| 4 | ALGLUCOSIDASE ALFA | 16 | 0.0066 |
| 5 | IDURSULFASE | 24 | 0.0060 |
| 6 | ELOSULFASE ALFA | 33 | 0.0060 |
| 7 | LANADELUMAB-FLYO | 18 | 0.0056 |
| 8 | ETEPLIRSEN | 12 | 0.0050 |
| 9 | COAGULATION FACTOR IX (RECOMBINANT), FC FUSION PROTEIN | 12 | 0.0048 |
| # | Drug class | Count |
|---|---|---|
| 0 | Endothelin Receptor Antagonist [EPC] | 545 |
| 1 | Prostacycline Vasodilator [EPC] | 509 |
| 2 | Phosphodiesterase 5 Inhibitor [EPC] | 317 |
| 3 | Integrin Receptor Antagonist [EPC] | 248 |
| 4 | Corticosteroid [EPC] | 225 |
| 5 | Nonsteroidal Anti-inflammatory Drug [EPC] | 194 |
| 6 | Osmotic Laxative [EPC] | 158 |
| 7 | Loop Diuretic [EPC] | 148 |
| 8 | Complement Inhibitor [EPC] | 138 |
| 9 | Benzodiazepine [EPC] | 118 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Antithrombin-directed RNA Interaction [EPC] | 1 | 0.0179 |
| 1 | Interleukin-5 Antagonist [EPC] | 11 | 0.0160 |
| 2 | Plasma Kallikrein Inhibitor [EPC] | 24 | 0.0100 |
| 3 | Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme [EPC] | 104 | 0.0078 |
| 4 | Small Interfering RNA [EPC] | 1 | 0.0063 |
| 5 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 18 | 0.0053 |
| 6 | Provitamin D2 Compound [EPC] | 116 | 0.0039 |
| 7 | Prostacycline Vasodilator [EPC] | 509 | 0.0037 |
| 8 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 9 | Integrin Receptor Antagonist [EPC] | 248 | 0.0028 |